Ocular Therapeutix Inc.

16.52+1.04+6.72%Vol 1.13M1Y Perf 418.85%
Nov 25th, 2020 16:00 DELAYED
BID16.28 ASK16.52
Open15.50 Previous Close15.48
Pre-Market- After-Market-
 - -%  - -
Target Price
14.60 
Analyst Rating
Strong Buy 1.00
Potential %
-11.62 
Finscreener Ranking
★★ —    46.80
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+ —    37.96
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     36.42
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.18B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
98.96 
Earnings Date
5th Nov 2020

Today's Price Range

15.5016.66

52W Range

3.1416.66

5 Year PE Ratio Range

-2.40-3.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
12.69%
1 Month
70.49%
3 Months
75.74%
6 Months
139.07%
1 Year
418.85%
3 Years
342.90%
5 Years
65.37%
10 Years
-

TickerPriceChg.Chg.%
OCUL16.521.04006.72
AAPL116.030.86000.75
GOOG1 771.432.55000.14
MSFT213.870.01000.00
XOM40.81-1.1700-2.79
WFC28.59-0.0200-0.07
JNJ143.68-0.1900-0.13
FB275.59-1.3300-0.48
GE10.500.05000.48
JPM122.03-1.2900-1.05
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.60
0.91
11.41
-13.00
Leverage Ratio -27.00
ProfitabilityValueIndustryS&P 500US Markets
81.80
-724.60
-702.00
-2 598.80
-
RevenueValueIndustryS&P 500US Markets
12.31M
0.17
68.84
34.45
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.23-0.1726.09
Q02 2020-0.32-0.34-6.25
Q01 2020-0.40-0.41-2.50
Q04 2019-0.42-0.47-11.90
Q03 2019-0.46-0.452.17
Q02 2019-0.42-0.57-35.71
Q01 2019-0.42-0.45-7.14
Q04 2018-0.37-0.42-13.51
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.1056.52Positive
12/2020 FY-0.8022.33Positive
3/2021 QR-0.1623.81Positive
12/2021 FY-0.4623.33Positive
Next Report Date-
Estimated EPS Next Report-0.23
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.13M
Shares Outstanding71.39M
Trades Count8.79K
Dollar Volume18.97M
Avg. Volume998.38K
Avg. Weekly Volume1.01M
Avg. Monthly Volume1.16M
Avg. Quarterly Volume1.25M

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock closed at 16.52 per share at the end of the most recent trading day (a 6.72% change compared to the prior day closing price) with a volume of 1.13M shares and market capitalization of 1.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 167 people. Ocular Therapeutix Inc. CEO is Antony C. Mattessich.

The one-year performance of Ocular Therapeutix Inc. stock is 418.85%, while year-to-date (YTD) performance is 318.23%. OCUL stock has a five-year performance of 65.37%. Its 52-week range is between 3.14 and 16.66, which gives OCUL stock a 52-week price range ratio of 98.96%

Ocular Therapeutix Inc. currently has a PE ratio of -8.10, a price-to-book (PB) ratio of 171.53, a price-to-sale (PS) ratio of 86.93, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -99.19%, a ROC of -144.78% and a ROE of -2 391.73%. The company’s profit margin is -%, its EBITDA margin is -702.00%, and its revenue ttm is $12.31 Million , which makes it $0.17 revenue per share.

Of the last four earnings reports from Ocular Therapeutix Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Ocular Therapeutix Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Ocular Therapeutix Inc. is Strong Buy (1), with a target price of $14.6, which is -11.62% compared to the current price. The earnings rating for Ocular Therapeutix Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ocular Therapeutix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ocular Therapeutix Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.78, ATR14 : 0.92, CCI20 : 151.47, Chaikin Money Flow : 0.01, MACD : 0.90, Money Flow Index : 83.91, ROC : 36.95, RSI : 71.72, STOCH (14,3) : 94.98, STOCH RSI : 0.90, UO : 67.60, Williams %R : -5.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ocular Therapeutix Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (83.33 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (16.67 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.33
Strong Buy
1.40

Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

CEO: Antony C. Mattessich

Teplephone: +1 781 357-4000

Address: 15 Crosby Drive, Bedford 01730, MA, USA

Number of employees: 167

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

33%67%

Bearish Bullish

53%47%

Bearish Bullish

59%41%

Bearish Bullish

48%52%

News

Stocktwits